Business
Senhwa Biosciences Highlights Breakthroughs in Dual First-in-Class Drug Programs at Annual Shareholders' Meeting Today
Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company, held its 2025 Annual Shareholders' Meeting today, chaired by Chairman Mr. Benny T. Hu. The company delivered updates on its ongoing drug development programs, outlining four key strategic milestones poised to drive its transformative growth:
About this update from Senhwa Biosciences Inc
[{"type":"text","content":"TAIPEI and SAN DIEGO, June 25, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company, held its 2025 Annual Shareholders' Meeting today, chaired by Chairman Mr. Benny T. Hu. The company delivered updates on its ongoing drug development programs, outlining four key strategic milestones poised to drive its transformative growth:","length":380,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Senhwa Biosciences, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Senhwa Biosciences, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":213,"height":54,"url":"https://media.zenfs.com/en/prnewswire.com/733155187d97c2430a91423c1587523b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3NCDoiso4s2Ko03dxAmxgQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNg--/https://media.zenfs.com/en/prnewswire.com/733155187d97c2430a91423c1587523b","width":213,"height":54}},"href":"https://mma.prnewswire.com/media/1933477/Senhwa_Logo_Logo_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"list","items":[{"val":[{"type":"text","content":"Launch of a new HIV "Functional Cure" strategic program","length":65,"tagName":"p"}]},{"val":[{"type":"text","content":"Advancement of partnership discussions with leading global immunotherapy companies","length":82,"tagName":"p"}]},{"val":[{"type":"text","content":"Active negotiations of multiple licensing opportunities","length":55,"tagName":"p"}]},{"val":[{"type":"text","content":"Dual-engine therapeutic breakthroughs from CX-4945 and CX-5461","length":62,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":264,"olType":false},{"type":"text","content":"Silmitasertib (CX-4945): Unlocking New Hope for HIV Cure","length":56,"tagName":"p"},{"type":"text","content":"In March, Senhwa made the strategic decision to discontinue its Community-Acquired Pneumonia clinical trial, prompting investor concern. This shift, based on compelling interim findings, redirected focus to the promising potential of CX-4945 in HIV treatment.","length":259,"tagName":"p"},{"type":"text","content":"Dr. Jason Huang, Acting CEO and Chief Medical Officer, revealed that in HIV-positive participants within the Community-Acquired Pneumonia study, a significant and rapid increase in a key immune biomarker was observed, potentially reflecting a m...